Reflections: What Really Matters  |  Teacher Insights: New Harvard Online course course prepares professionals for a data-driven world  |  Parent Interventions: Research shows lullabies in any language relax babies  |  International Edu News: 'Plastic bags could be 'eco-friendlier' than paper and cotton bags'  |  Leadership Instincts: Start-up with plastic waste recycling solution wins top prize at ideasinc 2020  |  International Edu News: Frailty, old age and comorbidity main predictors of death from Covid-19  |  Leadership Instincts: Cyber centre to reduce digital harm  |  Policy Indications: New funding to improve water security for 10 million people in Africa and Asia  |  International Edu News: UCL hosts global conference on UN Sustainable Development Goals  |  International Edu News: Medium-term impact of COVID-19 revealed in new study  |  International Edu News: Extremely rapid diagnostic test for Covid-19  |  Teacher Insights: Cambridge University Press to join with Cambridge Assessment  |  National Edu News: Minister inaugurates new Diamond Jubilee Lecture Hall Complex of NIT Jamshedpur  |  Education Information: CSIR partnered clinical trials website “CUReD” on Repurposed Drugs for Covid- 19  |  Teacher Insights: The 6th India International Science Festival to be held in Virtual format  |  
September 22, 2020 Tuesday 11:00:19 AM IST

India’s first CRISPR Covid-19 test approved for use in India

National Edu News

The Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) test, powered by CSIR-IGIB(Institute of Genomics and Integrative Biology) FELUDA, received regulatory approvals today from the Drug Controller General of India (DCGI) for commercial launch, as per ICMR guidelines, meeting high quality benchmarks with 96% sensitivity and 98% specificity for detecting the novel coronavirus. This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus.CRISPR is a genome editing technology to diagnosing diseases.

The Tata CRISPR test is the world’s first diagnostic test to deploy a speciallyadapted Cas9 protein to successfully detect the virus causing Covid-19. This marks a significant achievement for the Indian scientific community, moving from R&D to a high-accuracy, scalable and reliable test in less than 100 days. The Tata CRISPR test achieves accuracy levels oftraditional RT-PCR tests, with quicker turnaround time, less expensive equipment, and better ease of use. Moreover, CRISPR is a futuristic technology that can also be configured for detection of multiple other pathogens in the future.

The effort is the result of a fruitful collaboration between the scientific community and industry. The Tata Group has worked closely with CSIR-IGIB and ICMR to create a high-quality test that will help the nation ramp up Covid-19 testing quickly and economically, with a ‘Made in India’ product that is safe, reliable, affordable, and accessible. 

Girish Krishnamurthy, CEO, TATA Medical and Diagnostics Ltd, said, “The approval for the Tata CRISPR test for COVID-19 will give a boost to the country’s efforts in fighting the global pandemic. The commercialization of the Tata CRISPR test reflects the tremendous R&D talent in the country, which can collaborate to transform India’s contributions to the global healthcare and scientific research world.”




Comments